** Shares of healthcare payments firm Waystar up 1.5% at $31.60
** Raymond James upgrades stock rating to "strong buy" from "outperform", maintains PT of $40
** The current valuation does not reflect the potential durability of double-digit growth amid broader secular shifts in healthcare to more modern technology - brokerage
** Growing healthcare complexity will only compound the regulatory and administrative burden on providers, which we think will disproportionally benefit vertical SaaS players with a suite sale - Raymond James
** Avg. rating of 10 brokerages for the stock is a "buy"; the median PT is $36, according to data compiled by LSEG
** As of last close, shares up 44.8% from WAY's June IPO price of $21.50
(Reporting by Sukriti Gupta in Bengaluru)
((Sukriti.Gupta@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。